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Abstract
Background: Detecting epistatic interactions plays a significant role in improving pathogenesis, prevention,
diagnosis, and treatment of complex human diseases. Applying machine learning or statistical methods to epistatic
interaction detection will encounter some common problems, e.g., very limited number of samples, an extremely
high search space, a large number of false positives, and ways to measure the association between disease markers
and the phenotype.
Results: To address the problems of computational methods in epistatic interaction detection, we propose a
score-based Bayesian network structure learning method, EpiBN, to detect epistatic interactions. We apply the
proposed method to both simulated datasets and three real disease datasets. Experimental results on simulation
data show that our method outperforms some other commonly-used methods in terms of power and sample-
efficiency, and is especially suitable for detecting epistatic interactions with weak or no marginal effects.
Furthermore, our method is scalable to real disease data.
Conclusions: We propose a Bayesian network-based method, EpiBN, to detect epistatic interactions. In EpiBN, we
develop a new scoring function, which can reflect higher-order epistatic interactions by estimating the model
complexity from data, and apply a fast Branch-and-Bound algorithm to learn the structure of a two-layer Bayesian
network containing only one target node. To make our method scalable to real data, we propose the use of a
Markov chain Monte Carlo (MCMC) method to perform the screening process. Applications of the proposed
method to some real GWAS (genome-wide association studies) datasets may provide helpful insights into
understanding the genetic basis of Age-related Macular Degeneration, late-onset Alzheimer’s disease, and autism.
Background
To identify genetic variants that affect susceptibility of a
variety of diseases, genome-wide association studies
(GWAS) genotype a dense set of common SNPs (Single
Nucleotide Polymorphism) and test allelic frequencies
among a cohort of affected people and non-affected
people [1]. Traditional analysis methods for GWAS data
only consider one SNP at a time and test its association
with disease. This type of analysis strategy is only suita-
ble for simple Mendelian disorders. Some common
complex diseases such as various types of cancers, cardi-
ovascular disease, and diabetes are influenced by multi-
ple genetic variants. Therefore, detecting high-order
epistasis, which refers to the interactive effect of two or
more genetic variants on complex human diseases, can
help to unravel how genetic risk factors confer suscept-
ibility to complex diseases [2]. However, the very large
number of SNPs checked in a typical GWAS and the
enormous number of possible SNP combinations make
detecting high-order epistatic interactions from GWAS
data computationally challenging [3]. Moreover, how to
measure the association between a set of SNPs and the
phenotype presents another grand statistical challenge.
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During the past decade, two types of heuristic compu-
tational methods have been proposed to detect epistatic
interactions: prediction/classification-based methods and
association-based methods. Prediction/classification-
based methods try to find the best set of SNPs, which
can generate the highest prediction/classification accu-
racy including, for example, multifactor dimensionality
reduction (MDR) [4], penalized logistic regression (e.g.,
stepPLR [5], and lassoPLR [6]), support vector machine
(SVM) [7], and random forest [8]. MDR is a non-para-
metric and model-free method based on constructing a
risk table for every SNP combination [4]. If the case and
control ratio in a cell of this risk table is larger than 1,
MDR will label it as “high risk”, otherwise, “low risk”. By
the risk table, MDR can predict disease risk and will
select the SNP combination with the highest prediction
accuracy. StepPLR and lassoPLR make some modifica-
tions to avoid the overfitting problems that standard
logistic regression methods suffer from [9] when detect-
ing epistatic interactions. For example, stepPLR com-
bines the logistic regression criterion with a penalization
of the L2-norm of the coefficients. This modification
makes stepPLR more robust to high-order epistatic
interactions [5]. Two machine learning methods: SVM
[7] and random forest [8] have also been applied to
detecting epistatic interactions. Machine learning meth-
ods are based on binary classification (prediction) and
treat cases as positives and controls as negatives in SNP
data. They use SVM or random forest as a predictor
and select a set of SNPs with the highest prediction/
classification accuracy by feature selection. Some predic-
tion/classification-based methods can only be applied to
small-scale analysis (i.e., a small set of SNPs) due to
their computational complexity. Moreover, almost all
prediction/classification-based methods tend to intro-
duce a large number of false positives, which may result
in a huge cost for further biological validation experi-
ments [10].
Bayesian epistasis association mapping (BEAM) is a
scalable and association-based method [11]. It partitions
SNPs into three groups: group 0 is for normal SNPs,
group 1 contains disease SNPs affecting disease risk
independently, and group 2 contains disease SNPs that
jointly contribute to the disease risk (interactions).
Given a fixed partition, BEAM can get the posterior
probability of this partition from SNP data based on
Bayesian theory. A Markov Chain Monte Carlo method
is used to reach the optimal SNP partition with maxi-
mum posterior probability in BEAM. One drawback of
BEAM is that identifying both single disease SNP and
SNP combinations simultaneously makes BEAM over-
complex and weakens its power.
Recently, we propose a new Markov blanket-based
method, DASSO-MB, to detect epistatic interactions in
case-control studies [10]. The Markov Blanket is a mini-
mal set of variables, which can completely shield the tar-
get variable from all other variables based on Markov
condition property [12]. Thus, Markov blanket methods
can detect the causal disease SNPs with the fewest false
positives. Furthermore, the heuristic search strategy in
Markov blanket methods can avoid the time-consuming
training process as in SVM and random forests. How-
ever, the faithfulness assumption in Markov blanket
methods, which can hardly always be ensured, may hin-
der their applications in detecting epistatic interactions
[13].
In this paper, we address the two critical challenges
(small sample sizes and high dimensionality) in epistatic
interaction detection by introducing a score-based Baye-
sian network structure learning method, EpiBN (Epi-
static interaction detection using Bayesian Network
model), which employs a Branch-and-Bound technique
and a new scoring function. Bayesian networks provide
a succinct representation of the joint probability distri-
bution and conditional independence among a set of
variables. In general, a score-based structure learning
method for Bayesian networks first defines a scoring
function reflecting the fitness between each possible
structure and the observed data, and then searches for a
structure with the maximum score. Comparing to Mar-
kov blanket methods, the merits of applying score-based
Bayesian network structure learning method to epistatic
interaction detection include: (1) the faithfulness
assumption can be relaxed and (2) heuristic search
method can solve the classical XOR (Exclusive or) pro-
blem [14]. We apply the EpiBN method to simulated
datasets based on four disease models and three real
datasets: Age-related Macular Degeneration (AMD)
dataset, late-onset Alzheimer’s disease (LOAD) dataset,
and autism dataset. We demonstrate that the proposed
method outperforms some commonly-used methods
such as SVM, MDR, and BEAM, especially when the
number of samples is small.
Methods
Bayesian networks: a brief introduction
A Bayesian network is a directed acyclic graph (DAG) G
consisting of nodes corresponding to a random variable
set {X1, X2, ..., Xn} and edges between nodes, which
determine the structure of G and therefore the joint
probability distribution of the whole network [15]. For
three random variables (nodes) X, Y and Z, if the prob-
ability distribution of X conditioned on both Y and Z is
equal to the probability distribution of X conditioned
only on Y, i.e., P(X|Y, Z) = P(X|Y), X is conditionally
independent of Z given Y. This conditional indepen-
dence is represented as(X ⊥ Z | Y) [16]. The DAG G
encodes local Markov assumption: each variable is
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conditionally independent of its nondescendants, given
its parents in G. By applying the local Markov assump-
tion, the joint probability distribution J can be repre-
sented as
P(X1, ..., Xn) =
n∏
i=1
P(Xi|Pa(Xi)) (1)
where Pa(Xi) denotes the set of parents of Xi in G.
Therefore, there are two components in a Bayesian net-
work. The first component is the DAG G reflecting the
structure of the network. The second component, θ,
describes the conditional probability distribution P(Xi|Pa
(Xi)) to specify the unique distribution J on G.
Bayesian networks provide models of causal influence
and allow us to explore causal relationships, perform
explanatory analysis, and make predictions. Genome-wide
association studies attempt to identify the epistatic interac-
tion among a set of SNPs, which are associated with one
certain type of disease. Therefore, we can use Bayesian
networks to represent the relationship between genetic
variants and a phenotype (disease status). The n SNP
nodes and the disease status/label node form a two-layer
Bayesian network and we want to determine which SNP
nodes are the parent nodes of the disease status node. In
this type of Bayesian network, we only allow edges from
SNP nodes to the disease status node. Edges from the dis-
ease status node to SNP nodes and edges among SNP
nodes are prohibited.
By modelling the association between SNPs and the
disease status based on Bayesian networks, we transform
detecting epistatic interactions into structure learning of
Bayesian networks from GWAS data. There are two
types of structure learning methods for Bayesian net-
works: constraint-based methods and score-and-search
methods. The constraint-based methods first build a ske-
leton of the network (undirected graph) by a set of
dependence and independence relationships. Next they
direct links in the undirected graph to construct a direc-
ted graph with d-separation properties corresponding to
the dependence and independence determined [17,18].
Although constraint-based methods are developed with a
rigorous theoretical foundation, errors in conditional
dependence and independence will affect the stability of
constraint-based methods, especially for small sample
problems, which is also a problem of Markov Blanket
methods in detecting epistatic interactions. Therefore, in
this paper, we focus on score-and-search methods. The
score-and-search methods view a Bayesian network as a
statistical model and transform the structure learning of
Bayesian networks into a model selection problem [19].
To select the best model, a scoring function is needed to
indicate the fitness between a network and the data.
Then the learning task is to find the network with the
highest score. Thus, score-and-search methods typically
consist of two components, (1) a scoring function, and
(2) a search procedure. Next, we discuss in detail the pro-
posed EpiBN algorithm, which consists of three compo-
nents: scoring, searching, and screening.
EpiBN scoring: A new BN scoring function
One of the most important issues in score-and-search
methods is the selection of scoring function. A natural
choice of scoring function is the likelihood function.
However, the maximum likelihood score often overfits
the data because it does not reflect the model complexity.
Therefore, a good scoring function for Bayesian net-
works’ structure learning must have the capability of bal-
ancing between the fitness and the complexity of a
selected structure. There are several existing scoring
functions based on a variety of principles, such as the
information theory and minimum description length (e.g.
BIC score, AIC score, and MDL score) [20-22] and Baye-
sian approach (BDe score) [23].
Suppose that a dataset D includes n variables {X1, X2, ...,
Xn} and N samples, we can write a general information-
based scoring function as:
log P(D|S) = log P(D|θ̂S, S) − C(S)f (N) (2)
C(S) =
n∑
i=1
qi(ri − 1) (3)
where θ̂S is an estimate of parameters from the maxi-
mum likelihood method for the structure S, qi is the
number of configurations of the parent set Pa(Xi) of Xi,
ri is the number of states of Xi, C(S) represents the
structure complexity, and f(N) is a penalization function
[24]. The first term of this score scheme measures the
fitness between the structure and data, and the second
term reflects structure complexity. With the maximum
likelihood method [19], we can get
log(P(D|θ̂S, S)) =
n∑
i=1
qi∑
j=1
ri∑
k=1
Nijk log(Nijk/Nij) (4)
where Nijk is the number of instances where Xi takes
its k-th value and the set of variables Pa(Xi) takes its j-
th configuration; Nij is the number of instances where
the set of variables Pa(Xi) takes its j-th configuration.
Obviously, Nij =
∑ri
k=1
Nijk . Note that if we set f(N) = 1,
we get the AIC score as
log P(D|S) = log P(D|θ̂S, S) − C(S) (5)
Alternatively, if we set f(N) = 1/2 log(N), then we
obtain the BIC score as
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log P(D|S) = log P(D|θ̂S, S) − 1/2C(S) log(N) (6)
The BIC score and AIC score are derived from some
approximations when the number of samples N
approaches infinity [25]. If the number of samples is
small, the approximation in the inference of both AIC
and BIC scores can not hold any more and the structure
penalty term in Eq. (5) and Eq. (6) are not suitable [26].
When using information-based scores in the Bayesian
network model to detect epistatic interactions by
GWAS data, which show a non-skewed distribution, the
BIC score is too strict and prefers to select simple struc-
tures, while the AIC score prefers to select complex
structures [27].
We herein describe a new information-based scoring
function to detect epistatic interactions by Bayesian net-
work model. In the Bayesian network for epistatic inter-
action detection, we are only concerned with one target
node, the disease status node, and we want to detect its
parent SNP nodes. We represent the local structure
around the disease status node as LDS (Local Disease
Structure), which consists of the disease status node and
edges from candidate disease SNP nodes to the disease
status node. Because of the decomposability property of
information-based scoring function, the AIC score for
LDS is:
log P(D|LDS) = log P(D|θ̂LDS, LDS) − C(LDS)
=
q∑
j=1
r∑
k=1
Njk log(Njk/Nj) − q(r − 1)
(7)
where C(LDS) is the complexity of the local disease
structure, q is the number of configurations of parent
SNP nodes, r is the number of states of the disease sta-
tus node, Njk is the number of instances where the dis-
ease status node takes its k-th value and the parent SNP
nodes take their j-th configuration, Nj is the number of
instances where the parent SNP nodes take their j-th
configuration, and Nj =
∑r
k=1
Njk .
We start our search from an empty local disease
structure LDS0, and we can obtain the AIC score for
LDS0:
log P(D|LDS0) = log P(D|θ̂LDS0 , LDS0) − C(LDS0)
=
r∑
k=1
Nk log(Nk/N) − (r − 1)
(8)
where Nk is the number of instances in which the dis-
ease status node takes its k-th value, and N =
∑r
k=1
Nk .
For further inference, we use X for the target disease
status node and use Pa(X) for its parent SNP nodes.
The log-likelihood of LDS and LDS0 can also be
expressed as follows:
log P(D|θ̂LDS, LDS) = −N ∗ H(X|Pa(X)) (9)
log P(D|θ̂LDS0 , LDS0) = −N ∗ H(X)) (10)
where H(X) is the entropy of X and H(X|Pa(X)) is the
conditional entropy of X given its parent set Pa(X) [28].
Based on the concept of mutual information and
Eq. (7)-(10), the mutual information between X and
Pa(X) is:
MI(X, Pa(X)) = H(X) − H(X|Pa(X))
=
log P(D|θ̂LDS, LDS) − log P(D|θ̂LDS0 , LDS0)
N
(11)
i.e. the mutual information between X and Pa(X) coin-
cides with the difference between the log-likelihood of
LDS and LDS0 [24].
The G2 test is commonly used to test independence
and conditional independence between two variables for
discrete data. From the general formula for G2, we know
that the value of G2 can also be calculated from mutual
information [29]. Thus, we can write the G2 test value
between X and Pa(X) as:
G2(X, Pa(X)) = 2N(MI(X, Pa(X))) = 2N(H(X) − H(X|Pa(X))) (12)
The number of degrees of freedom for G2 test
between X and Pa(X) is:
DF(G2(X, Pa(X))) = (Cat(X) − 1)(Cat(Pa(X)) − 1)
= (r − 1)(q − 1) (13)
where Cat(V) is the number of categories of the vari-
able V, and thus Cat(X) = r and Cat(Pa(X)) = q [18].
It is interesting to note that the difference between the
complexity of LDS and LDS0 is equal to the degree of
freedom of G2(X, Pa(X)) by
C(LDS) − C(LDS0) = (r − 1)q − (r − 1)
= (r − 1)(q − 1) = DF(G2(X, Pa(X))) (14)
By applying Eq. (7)-(14), the difference of AIC scores
between LDS and LDS0 is:
log P(D|LDS) − log P(D|LDS0)
= N(MI(X, Pa(X)) − (r − 1)(q − 1)
= 1/2(G2(X, Pa(X)) − 2DF(G2(X, Pa(X))))
(15)
Thus, the AIC score becomes:
log P(D|LDS)
= 1/2(G2(X, Pa(X)) − 2DF(G2(X, Pa(X)))) + log P(D|LDS0)
(16)
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where log P(D|LDS0) is a constant.
The distribution of G2 asymptotically approximates to
that of c2 with the same number of degrees of freedom
[18]. The c2 distribution with k degrees of freedom has
a variance of 2k, and therefore 2DF(G2(X, Pa(X))) is the
variance of the corresponding G2 distribution. Since G2
(X, Pa(X)) reflects the bias, the AIC score in Eq. (16)
indicates a trade-off between bias and variance in terms
of the G2 statistic G2(X, Pa(X)) and its variance.
One problem for the AIC score in Eq. (5), Eq. (7), and
Eq. (16) is that the penalty term (the effective number of
parameters) in AIC score probably can not reflect the
model complexity (or variance) especially when applied to
SNP data with a non-skewed distribution. We can confirm
this by comparing 2DF(G2(X, Pa(X))) with the true var-
iance of G2(X, Pa(X)) from SNP data. There is a large
deviation between them when Pa(X) contains more than
two parent nodes. The more parent nodes Pa(X) contains,
the larger the deviation is because of the increasing model
complexity and hence the increasing ‘difficulty in estima-
tion’ [30]. One simple but practical way to consider and
estimate the model complexity in AIC score is replacing
2DF(G2(X, Pa(X))) in Eq. (16) with the true variance of G2
(X, Pa(X)) from data and our new epistatic scoring func-
tion (EpiScore) becomes:
EpiScore(LDS : D) = log P(D|LDS)
= 1/2(G2(X, Pa(X)) − VarD(G2(X, Pa(X)))) + log P(D|LDS0)
(17)
where VarD(G
2(X, Pa(X))) comes from the estimation of
the variance of the corresponding G2 distribution from
data. Our new scoring function estimates the penalty term
from the data to make it consistent with the data, which is
similar to the DIC (Deviance Information Criterion) score
trying to identify models that best explain the observed
data [30].
Due to the estimation of the variance of G2(X, Pa(X))
from data in Eq. (17), EpiScore is not score-equivalent.
However, we are not very concerned about this: there are
no equivalent structures in the two-layer Bayesian network
for the restriction on the direction of edges we describe in
the previous section.
EpiBN searching: A Branch-and-Bound algorithm for local
structure learning
The computational task in score-and-search methods is to
find a network structure with the highest score. The
searching space consists of a super-exponential number of
structures and thus exhaustively searching optimal struc-
ture from data for Bayesian networks is NP-hard [31].
One simple heuristic search algorithm is greedy hill-climb-
ing algorithm, where three types of operators are defined
to change one edge at each step: adding an edge, removing
an edge, and reversing an edge. By these three operators,
we can construct the local neighbourhood of the current
network. Then we select the network with the highest
score in the local neighbourhood to get the maximal gain.
This process can be repeated until it reaches a local maxi-
mum. However, greedy hill-climbing algorithm cannot
guarantee a global maximum [19]. Other structure learn-
ing methods for Bayesian networks include Branch-and-
Bound (B&B) [28,32] and Markov chain Monte Carlo [33].
We employ B&B algorithm in our study because the
B&B algorithm can guarantee the optimal results in a sig-
nificantly reduced search time compared to exhaustive
search. Our EpiBN method uses B&B algorithm to search
a local disease structure that maximizes the EpiScore in
Eq. (17). The pseudo code of EpiBN is shown in Figure 1.
In EpiBN, the procedure BN_B&B starts from an empty
parent node set and constructs a depth-first search tree
to find the optimal parent (disease SNPs) set for the dis-
ease status node. In our B&B search, instead of using the
pruning strategy as in [28], which sets a lower bound for
the MDL score to prune the search tree, we stop the
recursive calls when we observe that the score will
decrease on the children state of the current state. This
strategy cannot guarantee global optima theoretically.
However, it will significantly speed up the search process
and perform well practically.
To guarantee to find the parent set with the highest
EpiScore, we can use the upper bound of the EpiScore
to prune the search tree. We notice the G2 function in
Eq. (12) has the property:
0 ≤ G2(X, Pa(X)) = 2N(H(X) − H(X|Pa(X))) ≤ 2N ∗ H(X) (18)
When adding a SNP node q into the parent set V1, the
variance of the corresponding G2 distribution, the pen-
alty term in Eq. (17), will increase by VarD(G
2(X, V2)) -
VarD(G
2(X, V1)). On the other hand, the G
2(X, V1) will
increase at most by 2N*H(X) because the value of
entropy H(X|Pa(X)) will decrease and is nonnegative.
Hence, if we find
VarD(G2(X, V2)) − VarD(G2(X, V1)) > 2N ∗ H(X)(19)
adding a SNP node q into the current parent set V1
will not increase the EpiScore and thus any further
search along the branch is useless. Essentially, the upper
bound of the EpiScore is
EpiScore(LDS : D) = log P(D|LDS) ≤ N ∗ H(X) + log P(D|LDS0) (20)
EpiBN screening: MCMC screening method for real
datasets
Even though the B&B algorithm uses an upper score
bound to reduce the searching space, it still has an
exponential time complexity in the worst case and is
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not feasible to be directly applied to real GWAS data.
Therefore, an efficient screening method is necessary.
Traditional screening methods assign a score to every
single SNP and select a subset of SNPs with high scores.
However, these methods ignore the joint effect of SNPs
on disease and are not suitable for detecting epistatic
interactions from real GWAS data.
In this paper, we use the Markov chain Monte Carlo
(MCMC) method [33] to perform the screening process.
In the Bayesian network for epistatic interaction detec-
tion, we use a Metropolis-Hastings method to build a
Markov chain to get the posterior probability for each
edge from the SNP nodes to the disease status node. At
each step of the Markov chain, we use two types of
moves: add an edge and remove an edge. The proposed
move is accepted with probability
α = min{1, Rα} (21)
where
Rα =
#(nbd(LDS))P(LDS′ |D)
#(nbd(LDS′))P(LDS|D) (22)
where #(nbd(LDS)) is the cardinality of the neighbour-
hood of the current local disease structure and LDS’ is
the candidate local disease structure in each step of the
Markov chain. Since LDS and LDS’ differ in one move,
the ratio #(nbd(LDS))/#(nbd(LDS’)) is one. In addition,
the posterior probability of the local disease structure, P
(LDS|D), is that P(LDS|D) ∝ P(D|LDS) P(LDS) and we
take a uniform distribution over the considered local
disease structures. Therefore, the acceptance ratio in Eq.
(22) becomes:
Rα = P(D|LDS′)/P(D|LDS) (23)
The likelihood of local disease structure, P(D|LDS),
can be calculated by Eq. (17). Based on the result from
MCMC method, we select SNP nodes associated with
edges whose posterior probabilities larger than 0. Since
we consider the association of multiple SNPs with dis-
ease status at each step of the Markov chain in our
MCMC method, the potential disease SNPs related with
epistatic interactions will be kept in the final subset of
SNPs.
Results
Analysis of Simulated Data
Simulated Data We first evaluate the proposed EpiBN
method on four simulated data sets, which are generated
Figure 1 EpiBN Algorithm.
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from three commonly used two-locus epistatic models
in [9] and one three-locus epistatic model developed in
[11]. Model-1 is a multiplicative model, model-2 demon-
strates two-locus interaction multiplicative effects, and
model-3 specifies two-locus interaction threshold effects.
There are three disease loci in model-4 [11]. Some cer-
tain genotype combinations can increase disease risk in
model-4 and there are almost no marginal effects for
each disease locus.
We generate data based on the similar parameter set-
tings as in [9-11] for three parameters associated with
each model: the marginal effect of each disease locus (l),
the minor allele frequencies (MAF) of both disease loci,
and the strength of linkage disequilibrium (LD, quantified
by the squared correlation coefficient r2 calculated from
allele frequencies) between the unobserved disease locus
and a genotyped locus [9]. For each parameter setting on
each model, we generate 50 datasets and each dataset
contains 100 markers genotyped for 1,000 cases and
1,000 controls. To measure the performance of each
method, we use power as our evaluation criterion, which
is defined as the proportion of simulated datasets in
which only the true diseases associated markers are iden-
tified without any false positives.
EpiBN versus BEAM, SVM, and MDR We first com-
pare EpiBN with three methods: BEAM, SVM, and
MDR on the four simulated disease models. The BEAM
software is downloaded from http://www.fas.harvard.
edu/~junliu/BEAM and we set the threshold of the B
statistic as 0.1 [11]. For SVM, we use LIBSVM with a
RBF kernel to detect gene-gene interactions. A grid
search is used for selecting optimal parameters. Instead
of using the exhaustive greedy search strategy for SNPs
as in [7], which is very time-consuming and infeasible to
large-scale datasets, we turn to a search strategy used in
[8]. First we rank SNPs based on the mutual informa-
tion between SNPs and disease status label that is 0 for
the control and 1 for the case. Then, we use a sliding
window sequential forward feature selection (SWSFS)
algorithm in [8] based on SNPs rank. The window size
in SWSFS algorithm determines how robust the algo-
rithm could be and we set it to 20. Since MDR algo-
rithm can not be applied to a large dataset directly, we
first reduce the number of SNPs to 10 by ReliefF [34], a
commonly-used feature selection algorithm, and then
MDR performs an exhaustive search for a SNP set that
can maximize cross-validation consistency and predic-
tion accuracy. When one model has the maximal cross-
validation consistency and another model has the maxi-
mal prediction accuracy, MDR follows statistical parsi-
mony (selects the model with fewer SNPs). Our EpiBN
is written in Matlab. The results on the simulated data
are shown in Figure 2. As can be seen, among the four
methods, the EpiBN method performs the best, and
BEAM is the second best. One possible reason is that
BEAM tries to detect single disease locus and epistatic
interactions simultaneously. This strategy makes BEAM
unnecessarily over-complex. In most cases, the powers
of both MDR and SVM are much smaller than those of
the EpiBN and BEAM algorithms.
Our definition of power prohibits any false positives
and any false negatives and reflects the ability to pre-
cisely detect whole interactions [35]. Although we con-
sider both type I error and type II error and the
performance comparison is fair for each method in Fig-
ure 2, this type of definition of power seems stringent.
To explore both false positive rates and false negative
rates further, we measure the detection accuracy by pre-
cision and recall. Precision is the number of true disease
SNPs in the output divided by the number of detected
SNPs in the output, which reflects the false positive
rate. On the other hand, recall is the number of true
disease SNPs in the output divided by the number of
true known disease SNPs, which reflects the false
Figure 2 Performance comparison of EpiBN, BEAM, SVM, and MDR.
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negative rate. The Euclidean distance from perfect preci-
sion and recall is defined as:
√
(1 − precision)2 + (1 − recall)2 (24)
which combines precision and recall [36]. Table 1 pre-
sents the average precision, recall, and distance perfor-
mance about EpiBN, BEAM, and SVM on 50 datasets
for each model with MAF = 0.5 and r2 = 1. EpiBN
achieves a higher overall accuracy than both BEAM and
SVM on model-2, model-3, and model-4. Moreover, the
overall accuracy of EpiBN on model-4 is perfect. On
model-1, EpiBN is still better than SVM while it is
slightly worse than BEAM. BEAM shows the highest
precision on the first three models, but it intends to
miss more true positives. On the contrary, SVM demon-
strates the highest recall, however, at the cost of intro-
ducing more false positives [10]. We do not evaluate the
accuracy of MDR because the MDR software can only
test at most 4-way epistatic interactions.
EpiScore versus BIC score and AIC score We also com-
pare our EpiScore with BIC score and AIC score. For
BIC score and AIC score, we use the upper bound of
score in [28] and the same B&B algorithm as in EpiBN.
Table 2 presents the results on datasets with MAF = 0.5
and r2 = 1. Column “o” shows the times of correct detec-
tion of all disease SNPs in 50 datasets. Column “+” pre-
sents the total number of extra detected SNPs and
column “-” has the total number of missing disease SNPs.
For model-1, mode-2, and model-3, EpiScore performs
better than both BIC score and AIC score. BIC score can
not detect true disease SNPs at all and introduce many
false negatives due to its heavy penalty term. Comparing
to EpiScore, AIC score tends to introduce more false
positives and more false negatives. It is interesting to
notice that every score function can achieve perfect
power on model-4. The reason is that the relatively large
genotypic effect, θ, in model-4 can generate data with
skewed distribution, which can help all scoring function
detect true disease SNPs.
EpiBN versus Markov Blanket methods To demonstrate
the advantages of EpiBN over Markov Blanket methods,
we compare EpiBN with three Markov Blanket methods:
interIAMBnPC [12], PCMB [36], and our DASSO-MB
[10]. For interIAMBnPC, we use the Matlab toolbox Cau-
sal Explorer which contains the interIAMBnPC algorithm
[37]. We implement both PCMB and DASSO-MB in
Matlab. G2 test is used to test dependence and indepen-
dence in these three Markov Blanket methods and we set
the p-value threshold for G2 test as 0.01. Figure 3 shows
the results. These four methods demonstrate the similar
performance on the multiplicative model: model-1. On the
other three interaction models: model-2, model-3, and
model-4, EpiBN is better than these three Markov Blanket
methods. Disease SNPs in model-1 affects the disease risk
independently, which makes it easy for Markov Blanket
methods to detect them. Additionally, DASSO-MB is bet-
ter than the other two Markov Blanket methods: inter-
IAMBnPC and PCMB. This is because the backward
phase in DASSO-MB to remove false positives is not that
strict as in interIAMBnPC and PCMB. Hence, DASSO-
MB can keep SNP nodes having strong joint effects on dis-
ease status but not showing strong marginal effects in the
Markov Blanket. This also confirms that the faithfulness
assumption may hinder the application of Markov Blanket
methods in detecting epistatic interactions.
Sample efficiency Typically, GWAS can not generate a
large number of samples due to the high experiment
cost. Thus, the performance of various computational
methods for epistatic interaction detection in case of
small samples is important. We explore the effect of the
Table 1 Accuracy comparison of EpiBN, BEAM, and SVM.
Model Method Precision Recall Distance
1 EpiBN 0.76 ± 0.27 0.76 ± 0.27 0.34 ± 0.38
BEAM 0.87 ± 0.32 0.75 ± 0.34 0.32 ± 0.43
SVM 0.61 ± 0.29 0.91 ± 0.19 0.43 ± 0.31
2 EpiBN 0.90 ± 0.21 0.90 ± 0.20 0.14 ± 0.29
BEAM 0.91 ± 0.26 0.75 ± 0.31 0.29 ± 0.38
SVM 0.69 ± 0.29 0.95 ± 0.15 0.34 ± 0.31
3 EpiBN 0.78 ± 0.30 0.79 ± 0.30 0.31 ± 0.43
BEAM 0.83 ± 0.35 0.74 ± 0.37 0.34 ± 0.49
SVM 0.72 ± 0.28 0.88 ± 0.24 0.33 ± 0.35
4 EpiBN 1.00 ± 0.00 1.00 ± 0.00 0.00 ± 0.00
BEAM 0.41 ± 0.49 0.20 ± 0.29 1.05 ± 0.47
SVM 0.41 ± 0.32 0.61 ± 0.38 0.76 ± 0.40
Table 2 Comparison of EpiScore, BIC score, and AIC
score.
Model Score o + -
1 EpiScore 27 24 24
BIC score 0 0 57
AIC score 12 55 31
2 EpiScore 40 11 10
BIC score 40 11 10
AIC score 22 36 14
3 EpiScore 30 23 21
BIC score 0 0 57
AIC score 10 53 20
4 EpiScore 50 0 0
BIC score 50 0 0
AIC score 50 0 0
“o": times of correct detection of all disease SNPs in 50 datasets. “+": total
number of extra detected SNPs in 50 datasets. “-": total number of missing
disease SNPs in 50 datasets.
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number of samples on the performance of EpiBN, MDR,
BEAM and SVM. The parameters used are: l = 1.1 for
model-1, l = 0.9 for model-2, l = 1.8 for model-3, and θ
= 7 for model-4. To test the scalability of EpiBN on large
number of SNPs, we generate synthetic datasets contain-
ing different number of SNPs (40, 200, and 1000) geno-
typed for different number of samples (100, 200, 300,
400, 600, 1000, and 2000) with r2 = 1 and MAF = 0.5.
The results are shown in Figure 4. We find that EpiBN is
more sample-efficient than other methods in that it can
achieve the highest power when the number of samples is
the same. In addition, it needs fewer samples to reach the
perfect power comparing to other methods. BEAM is still
the second best. The powers of both MDR and SVM are
still smaller than those of the EpiBN and BEAM
algorithms. However, MDR and SVM demonstrate a bet-
ter performance comparing to the results in Figure 2. This
is perhaps due to the fact that increasing the marginal
effect size l for model-1, model-2, and model-3 makes the
detecting task suitable for the pre-filtering based methods
such as MDR and SVM. The result from model-4 is parti-
cularly interesting: EpiBN exhibits overwhelming superior-
ity over other three methods, as EpiBN yields a perfect
power even the number of samples is small (around 600),
which indicates that EpiBN is especially suitable for
detecting epistatic interactions with weak or no marginal
effects. From Figure 4, we can also find that increasing the
number of genotyping markers, like adding some noise to
the data, will impair the power of all methods, especially
in case of small samples.
Figure 3 Performance comparison of EpiBN with three Markov Blanket methods: interIAMBnPC, PCMB, and DASSO-MB.
Figure 4 Comparison of sample efficiency on datasets with different number of SNPs: (a) 40 SNPs, (b) 200 SNPs and (c) 1000 SNPs.
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Analysis of AMD Data
In this section and the following two sections, we apply
EpiBN to large-scale datasets in real genome-wide case-
control studies, which often require genotyping of
30,000-1,000,000 common SNPs. We first make use of
an Age-related Macular Degeneration (AMD) dataset
containing 116,204 SNPs genotyped with 96 cases and
50 controls [38] (i.e., high dimensionality and small
sample sizes). Multiple genetic factors cause AMD,
which is a complex retinal degenerative disorder. To
remove inconsistently genotyped SNPs, we perform the
same filtering process as in [11,38]. After filtering, there
are 97,327 autosomal SNPs remained.
We first perform the screening process and select 51
potential disease SNPs related with AMD by MCMC
method. Among these 51 selected SNPs, EpiBN detects
two associated SNPs showing the highest EpiScore:
rs380390 and rs2402053. Klein et al. demonstrated that
the first SNP, rs380390, is associated with AMD [38]. The
second SNP, rs2402053, is intergenic between TFEC and
TES in chromosome 7q31 [39]. Even though no evidences
show that rs2402053 is related with AMD, it is worth not-
ing that mutations in some genes on 7q31-q32 are
revealed in patients with retinal disorders [40]. Therefore,
rs2402053 may be a new genetic factor, on chromosome
7q, contributing to the underlying mechanism of AMD.
Analysis of LOAD Data
Late-onset Alzheimer’s disease (LOAD) is the most com-
mon form of Alzheimer’s disease and usually occurs in
persons over 65. It causes patients’ degeneration of the
ability of thinking, memory, and behaviour. The apolipo-
protein E (APOE) gene is one genetic factor that accounts
for affecting the risk of LOAD. There are three common
variants of the APOE gene: ε2, ε3, and ε4. The appearance
of the ε4 allele in a person’s APOE genotype increases the
LOAD risk [41]. Rieman et al. conducted genome-wide
association studies to detect other generic risk factors
related with LOAD [41]. They found 10 SNPs showing
significant association with LOAD in the APOE ε4 car-
riers. All these 10 SNPs are in the GRB-associated binding
protein 2 (GAB2) gene.
We download the LOAD GWAS data from http://www.
tgen.org/neurogenomics/data. After pre-processing, we
have 287,479 SNPs and 1408 samples (857 cases and 551
controls). EpiBN keeps APOE as one parent of the disease
status node and identifies two other SNPs: rs1931565 and
rs4505578, which may interact with APOE and affect the
LOAD risk. The rs1931565 SNP is intergenic between
ABCA4 and ARHGAP29 in chromosome 1p22. ABCA4 is
related with some brain-related diseases including star-
gardt disease 1, early-onset severe retinal dystrophy and
age-related macular degeneration [42]. On the other hand,
some ABC transporter family genes such as ABCA1,
ABCA2, ABCA7 and ABCA12 are associated with Alzhei-
mer’s disease [43]. Therefore, we can speculate that the
interaction among rs1931565, rs4505578 and APOE may
affect some brain functions and therefore increase the
LOAD risk. Our results do not contain any of the 10 SNPs
in GAB2 found in [41]. One reason is that Rieman et al.
only explored two-locus interactions related with LOAD.
In fact, the epistatic interactions are very complicated. If
we restrict the number of genetic risk factors as two, we
will miss some potential disease SNPs associated with
complex diseases.
Analysis of Autism Data
Autism is a common early onset neurodevelopmental
disorder, which affects the brain’s normal development
and impairs social interaction and communication. To
pinpoint the causal SNPs and genes involved in autism, a
large number of genotyping data have been generated
from subjects with and without autism. Some of the gen-
otyping data have been deposited on the AGRE (Autism
Genetic Resource Exchange) website http://www.agre.org
for further analysis by the research community. In this
paper, we analyse one of the largest genotype dataset
contributed by Children’s Hospital of Philadelphia
(CHOP), which contains 513,312 SNPs genotyped from
1784 cases and 2441 controls [44]. To reduce the search-
ing space and focus on more relevant SNPs, we only use
SNPs in autism-related genes. We first get information of
277 autism-related genes from the autism genetic data-
base (AGD) http://wren.bcf.ku.edu/[45]. Then we obtain
a list of 205,589 SNPs in these autism-related genes from
UCSC genome browser http://genome.ucsc.edu/[46]. The
CHOP dataset contains 9330 of these 205,589 SNPs.
Samples with missing rate > 10% and SNPs with missing
rate > 10%, MAF < 0.05, and p-value of HWE < 0.001
were removed. After applying the aforementioned filter-
ing process, our genotype dataset contains 4222 samples
(1783 cases, 2439 controls) and 8198 SNPs.
Heterogeneity of phenotypic presentation in autism
makes it difficult to detect epistatic interactions related
with this complex disorder [47]. One proposed approach
to reduce the phenotypic heterogeneity of autistic subjects
is dividing them into several subgroups by clustering
method on ADI-R (Autism Diagnostic Interview-Revised)
data [48]. The ADI-R is a clinical diagnostic interview to
assess autism in children and adults and contains 93 items
about behaviours in three domains: quality of social inter-
action, communication and language ability, and repetitive,
restricted and stereotyped interests and behaviour [49]. In
this paper, we use an alternative method to reduce the
phenotypic heterogeneity: biclustering [50]. Biclustering
methods can identify subgroups of autism samples that
show similar behaviour patterns on a specific subset of
ADI-R items. By applying the biclustering method [50], we
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find a bicluster of constant value in 235 subjects for 8 out
of 77 numerically scored ADI-R items (0 = normal; 3 =
most severe). These autistic subjects have the same ADI-R
score (i.e., 3 which is most severe) on the 8 ADI-R items
which are: CCONVER, CINAPPQ, CPRON, CNEOID,
CVERRIT, CINR, CSPEECH, and CFRIEND. Most of
these 8 items are about verbal and nonverbal communica-
tion. Therefore these 235 autism samples may represent a
subset with the most severe communication problems.
To explore the genetic basis in the identified more
homogeneous subset, we use the SNP data for these 235
autistic subjects (cases) and 2439 controls in CHOP data-
set. The MCMC method first selects 111 candidate SNPs.
Then our EpiBN detects an epistatic interaction of three
SNPs: rs706363, rs7780487, and rs12536378. The first
SNP, rs706363, is on the autism candidate gene DAB1 on
chromosome 1. Both rs7780487 and rs12536378 are on
the autism candidate gene DPP6 on chromosome 7. If we
search HPRD (Human Protein-protein Interaction Data-
base), we can find a pathway from DAB1 to DPP6:
DAB1–APLP2–PRNP–DPP6 [51]. This suggests a poten-
tial interaction between the detected SNPs using our
EpiBN, which warrants further investigations to assess
this in silico prediction by molecular functional
experiments.
Discussion
Jiang et al. also tried to use score-based Bayesian net-
work structure learning methods to detect epistatic
interactions [52]. They evaluated the performance of 22
BN scoring criteria by scoring all 1-SNP, 2-SNP, 3-SNP,
and 4-SNP Bayesian networks on simulation datasets
and showed that the BDeu score with large values of
hyperparameters a achieved the best performance. Since
the prior knowledge on the optimal a and the true
number of disease SNPs is unknown, their methods can
hardly address the two critical challenges (small sample
sizes and high dimensionality) in epistatic interaction
detection very well.
Conclusions
To address the two critical challenges (small sample sizes
and high dimensionality) in epistatic interaction detection
from GWAS data, several machine learning or statistical
methods have been proposed during the past decade.
However, these proposed machine learning or statistical
methods still encounter some problems: scalability to real
genome-wide dataset, tending to introduce false positives,
sample-efficiency, and poor performance when detecting
epistatic interactions with weak or no marginal effects.
In this paper, we propose a Bayesian network-based
method, EpiBN, to detect epistatic interactions. We
develop a new scoring function, which can reflect
higher-order epistatic interactions by estimating the
model complexity from data, and apply a fast B&B algo-
rithm to learn the structure of a two-layer Bayesian net-
work containing only one target node. To make our
method scalable to GWAS data, we propose the use of a
MCMC method to perform the screening process.
We apply the proposed method to both simulated
datasets based on four disease models and three real
datasets. Our experimental results demonstrate that our
method outperforms some other commonly-used meth-
ods and is scalable to GWAS data.
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